Quick Answer
Neumora Therapeutics, Inc. reported Earnings Per Share Diluted of $1.45 (loss) per share for the year ending 2025.
- Neumora Therapeutics, Inc. showed an increase of +5.2% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Neumora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2022: $1.06 (loss) per share | Q1 2023: $1.22 (loss) per share | Q2 2023: $1.28 (loss) per share | Q3 2023: $1.14 (loss) per share | Q1 2024: $0.34 (loss) per share | Q2 2024: $0.37 (loss) per share | Q3 2024: $0.45 (loss) per share | Q1 2025: $0.42 (loss) per share | Q2 2025: $0.33 (loss) per share | Q3 2025: $0.35 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Neumora Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 69.9%.
- Historical annual values: Fiscal year 2025: $1.45 (loss) per share | Fiscal year 2024: $1.53 (loss) per share | Fiscal year 2023: $3.63 (loss) per share | Fiscal year 2022: $4.81 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: